Hehuang Pharmaceutical (00013) is now up nearly 6%. As of press release, it has risen 5.21% to HK$28.25, with a turnover of HK$586.912 million.
The Zhitong Finance App learned that Hewang Pharmaceutical (00013) is now up nearly 6%. As of press release, it has risen 5.21% to HK$28.25, with a turnover of HK$586.912 million.
According to the news, Hutchison Pharmaceutical previously announced that it will present the latest and updated data from several studies on self-developed compounds at the American Association for Cancer Research (AACR) 2024 Annual Meeting to be held in San Diego, California, USA from April 5 to 10, 2024.
Ping An Securities pointed out that fruquintinib maintains a leading position in the global third-tier colorectal cancer market, and is being released rapidly after listing in the US; furoquintinib is expected to be approved for second-line gastric cancer indications, and domestic sales are expected to peak at more than 2 billion yuan; continued development in the research pipeline, and approval of new indications for various major products is expected to continue to catalyze a continuous increase in the company's value.